Technical Analysis for ACOR - Acorda Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 1.52 -3.80% -0.06
ACOR closed down 2.47 percent on Tuesday, November 19, 2019, on 58 percent of normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ACOR trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish -3.80%
Narrow Range Bar Range Contraction -3.80%
New 52 Week Low Weakness -3.80%
Wide Bands Range Expansion -3.80%
Down 3 Days in a Row Weakness -3.80%
Down 4 Days in a Row Weakness -3.80%
Down 5 Days in a Row Weakness -3.80%
Oversold Stochastic Weakness -3.80%
MACD Bearish Signal Line Cross Bearish -6.17%
New 52 Week Closing Low Bearish -6.17%

Older signals for ACOR ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally. In addition, it is developing Diazapam Nasal Spray, which is in NDA preparations for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase II clinical trials for cerebral palsy and post-stroke deficits; AC105, which is in Phase II clinical trials for the treatment of SCI and TBI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for SCI. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Chemistry Biopharmaceutical Health Antibodies Autoimmune Diseases Clinical Trial Multiple Sclerosis Heart Failure Central Nervous System Disorders Treatment Of Heart Failure Spinal Cord Injury
Is ACOR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 21.13
52 Week Low 1.57
Average Volume 1,690,156
200-Day Moving Average 7.7061
50-Day Moving Average 2.6154
20-Day Moving Average 2.0238
10-Day Moving Average 2.0175
Average True Range 0.2527
ADX 18.99
+DI 17.5016
-DI 31.6172
Chandelier Exit (Long, 3 ATRs ) 2.0619
Chandelier Exit (Short, 3 ATRs ) 2.3281
Upper Bollinger Band 2.6193
Lower Bollinger Band 1.4283
Percent B (%b) 0.13
BandWidth 58.849689
MACD Line -0.2323
MACD Signal Line -0.2089
MACD Histogram -0.0234
Fundamentals Value
Market Cap 73.56 Million
Num Shares 46.6 Million
EPS -0.94
Price-to-Earnings (P/E) Ratio -1.68
Price-to-Sales 2.27
Price-to-Book 1.76
PEG Ratio 0.51
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.76
Resistance 3 (R3) 1.78 1.73 1.73
Resistance 2 (R2) 1.73 1.69 1.73 1.72
Resistance 1 (R1) 1.66 1.66 1.64 1.64 1.71
Pivot Point 1.61 1.61 1.60 1.61 1.61
Support 1 (S1) 1.54 1.57 1.52 1.52 1.45
Support 2 (S2) 1.49 1.54 1.49 1.44
Support 3 (S3) 1.42 1.49 1.43
Support 4 (S4) 1.40